The human AKR1C2 can interconvert steroidal hormones from their active to inactive forms,37 thus, representing the potential drug target for the development of reagents in the treatment of hormone‐dependent cancers like prostate, breast and endometrial cancers, as well as in other diseases. This evidence concerns the gene AKR1C2 and endometrial cancer.